CYP4F11 as A Drug Target for Pancreatic Cancer (G57834)

Target Name: CYP4F11

NCBI ID: G57834

CYP4F11

CYP4F11 as A Drug Target for Pancreatic Cancer

CYP4F11 (CP4FB_HUMAN), a single-nucleotide polymorphism (SNP) in the C-pyruvate synthase gene (CYP4F11), is a drug target and a biomarker of pancreatic cancer. CYP4F11 is a key enzyme in the pyruvate pathway, which is a critical pathway for cellular energy metabolism. It is well established that mutations in the C-pyruvate synthase gene are associated with decreased levels of pyruvate, which can lead to a range of cellular and tissue effects, including decreased cellular energy production, increased cell size, and the formation of malignant cells.

Studies have shown that individuals with certain SNPs, including CYP4F11, are at an increased risk of developing pancreatic cancer. For example, a study by the National Cancer Institute found that individuals with the SNP rs6522224 were twice as likely to develop pancreatic cancer compared to individuals without the mutation. Another study by the American Cancer Society found that individuals with the SNP rs2286920 were also at an increased risk of pancreatic cancer.

In addition to its association with pancreatic cancer, CYP4F11 has also been shown to be involved in a number of other cellular processes. For example, it is involved in the production of ATP, which is the cell's primary energy source, as well as in the metabolism of glucose and fatty acids. It is also a key enzyme in the citric acid cycle, which is involved in the production of toxic derivatives that can contribute to cellular stress and the development of cancer.

Given its involvement in a number of cellular processes and its association with pancreatic cancer, CYP4F11 is an attractive drug target. Researchers have been exploring the use of drugs that can modulate CYP4F11 activity in order to treat pancreatic cancer. One approach is to use drugs that can inhibit the activity of CYP4F11, such as the prototype drug trastuzumab (T), which is a monoclonal antibody that targets the HER2 protein, which is a common aberration in pancreatic cancer cells.

Another approach is to use drugs that can modulate CYP4F11 activity and increase its levels in cancer cells, such as the drug rapamycin (R). Rapamycin is an immunosuppressant drug that is used to prevent the rejection of transplanted organs. It is also a potent inhibitor of CYP4F11 activity, and has been shown to increase the levels of CYP4F11 in cancer cells.

In addition to these drug approaches, researchers are also exploring the use of DNA-based therapies to modify CYP4F11 activity in pancreatic cancer cells. One approach is to use CRISPR/Cas9 technology to edit the DNA of cancer cells and introduce SNPs, such as the one in CYP4F11, into their genome. This would allow the cancer cells to produce the full range of cellular products that include CYP4F11, including the production of pyruvate, which could potentially contribute to the development of pancreatic cancer.

Overall, CYP4F11 is a promising drug target and biomarker for the development of pancreatic cancer. Further research is needed to fully understand its role in this disease and to develop effective treatments. By modulating CYP4F11 activity and identifying new drug targets, researchers hope to be able to improve treatment outcomes for pancreatic cancer.

Protein Name: Cytochrome P450 Family 4 Subfamily F Member 11

Functions: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids and their oxygenated derivatives (oxylipins) (PubMed:24138531, PubMed:15364545, PubMed:18065749). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:15364545, PubMed:18065749, PubMed:24138531). Catalyzes with high efficiency the oxidation of the terminal carbon (omega-oxidation) of 3-hydroxy fatty acids, such as 3-hydroxyhexadecanoic and 3-hydroxyoctadecanoic acids, likely participating in the biosynthesis of long-chain 3-hydroxydicarboxylic acids (PubMed:18065749, PubMed:19932081). Omega-hydroxylates and inactivates phylloquinone (vitamin K1), and menaquinone-4 (MK-4, a form of vitamin K2), both acting as cofactors in blood coagulation (PubMed:24138531). Metabolizes with low efficiciency fatty acids, including (5Z,8Z,11Z,14Z)-eicosatetraenoic acid (arachidonate) and its oxygenated metabolite 8-hydroxyeicosatetraenoic acid (8-HETE) (PubMed:15364545, PubMed:19932081). Catalyzes N- and O-demethylation of drugs such as erythromycin, benzphetamine, ethylmorphine, chlorpromazine, imipramine and verapamil (PubMed:15364545)

The "CYP4F11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP4F11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets